Neil Allan Johnson, Chief Executive Officer at Duke Capital, holds 7.79M shares in Duke Capital (Ticker: GB:DUKE), holds 330.00K shares in Marvel Biosciences Corp (Ticker: TSE:MRVL), holds 875.00K shares in Thiogenesis Therapeutics Corp (Ticker: TSE:TTI). Most recently, Neil Allan Johnson Bought ― shares of Duke Capital on Nov 15, 2024 for an estimated value of 100.00K.
What is the percentage of profitable transactions made by Neil Allan Johnson?
The percentage of profitable transactions made by Neil Allan Johnson is 46%.
What is the average return per transaction made by Neil Allan Johnson?
The average return per transaction made by Neil Allan Johnson is -6.70%.
What stocks does Neil Allan Johnson hold?
Neil Allan Johnson holds: GB:DUKE, TSE:DCF, CCORF, TSE:MRVL, TSE:TTI stocks.
What was Neil Allan Johnson’s latest transaction?
Neil Allan Johnson latest transaction was an Informative Buy of 100.00K.
What was Neil Allan Johnson's most profitable transaction?
Neil Allan Johnson’s most profitable transaction was an Informative Buy of GB:DUKE stock on October 9, 2017. The return on the trade was 18.80%.
What is Neil Allan Johnson's role in Duke Capital?
Neil Allan Johnson's role in Duke Capital is Chief Executive Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.